Friday, November 1, 2013

Antibody Engineering Poster: Development and Characterization of CEP-37248: Potent IL-12/23 antagonism via novel mode of receptor inhibition

Leading up to the Antibody Engineering Event, we'll be sharing the posters that will be featured in the Exhibit Hall.  Antibody Engineering & Therapeutics will take place December 8-12, 2013 in Huntington Beach, California.  For more information the program, download the agenda.  If you'd like to join us, as a reader of this blog, when you register to join us and mention code XD13172BLOGJP, you'll save 20% off the standard rate!

Featured Poster:  Development and Characterization of CEP-37248: Potent IL-12/23 antagonism via novel mode of receptor inhibition

Featured Presenter: Adam Clarke, Teva Pharmaceuticals

About the Poster: Antibodies against the p40 subunit of IL-12 and IL-23 have proven efficacious for the treatment of psoriasis, which is considered a largely IL-23-driven disease. However, in Crohn’s Disease, considered to have a major IL-12-driven component in addition to the role of IL-23, clinical efficacy has been less compelling. There is scope for more effective therapy through the development of therapeutics that more completely inhibit both IL-12 and IL-23. This presentation covers the development of CEP-37248, an anti–IL12/23 p40 monoclonal antibody that strongly antagonizes both IL-12 and IL-23. CEP-37248 was humanized and affinity matured to bind with high affinity to IL-12 and IL-23. The site on IL-12p40 to which CEP-37248 binds has been determined by X-ray crystallography and protein mutagenesis. When CEP-37248 binds to IL-12p40 it inhibits the IL-12 and IL-23 receptor-ligand complex in a novel manner, resulting in potent antagonist activity - when tested in IL-12- based cell activity assays CEP-37248 is orders of magnitude more potent then an existing anti-IL-12/23 antibody. This superior potency is also demonstrated in in vivo models. We conclude that CEP-37248 has the potential to be a more effective treatment for IL-12/23-driven autoimmune disease, warranting investigation in the clinic.

Do you have new research to share with your industry colleagues? Your poster can be featured in the Antibody Engineering Exhibit hall as well! Find out how here.  The deadline for poster submissions is November 1.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment